<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3342">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402944</url>
  </required_header>
  <id_info>
    <org_study_id>P00035140</org_study_id>
    <nct_id>NCT04402944</nct_id>
  </id_info>
  <brief_title>Pulmozyme to Improve COVID-19 ARDS Outcomes</brief_title>
  <official_title>Pulmozyme to Improve COVID-19 ARDS Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind placebo-controlled Phase II trial of recombinant human&#xD;
      deoxyribonuclease I (rhDNase I) - Pulmozyme - in mechanically ventilated patients with&#xD;
      COVID-19 pneumonia.&#xD;
&#xD;
      Patients admitted to the ICU with severe COVID-19 pneumonia who require mechanical&#xD;
      ventilation will be invited to participate in this study. Potential subjects will be&#xD;
      identified from medical record review or from direct contact with physicians. Investigators&#xD;
      will check medical history and confirm eligibility. Informed consent will be obtained from&#xD;
      either the patient or designated healthcare proxy.&#xD;
&#xD;
      60 subjects will be enrolled. After obtaining informed consent, patients will be randomized&#xD;
      2:1 to Pulmozyme 2.5 mg BID for up to 28 days or until they are no longer receiving&#xD;
      mechanical ventilation, whichever is sooner plus standard of care vs. placebo normal saline&#xD;
      2.5 ml plus standard of care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days at 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>Primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in airway resistance</measure>
    <time_frame>28 days</time_frame>
    <description>change in airway resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lung compliance</measure>
    <time_frame>28 days</time_frame>
    <description>Change in lung compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygenation (PaO2/FiO2 ratio)</measure>
    <time_frame>28 days</time_frame>
    <description>oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay (ICU and hospital)</measure>
    <time_frame>28 days</time_frame>
    <description>length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of barotrauma</measure>
    <time_frame>28 days</time_frame>
    <description>rate of batotrauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality.</measure>
    <time_frame>28 days</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Study Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmozyme</intervention_name>
    <description>Pulmozyme 2.5 mg BID</description>
    <arm_group_label>Study Drug</arm_group_label>
    <other_name>Dornase alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline 2.5 mL BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ICU admission for pneumonia complicated by respiratory failure.&#xD;
&#xD;
          -  RT-PCR (or equivalent) confirmed COVID-19 infection.&#xD;
&#xD;
          -  Intubated and on mechanical ventilation within 120 hours of initiation of mechanical&#xD;
             ventilation.&#xD;
&#xD;
          -  Age ≥ 3 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or known intolerance to Pulmozyme or Chinese Hamster Ovary cell products&#xD;
&#xD;
          -  History of moderate to severe asthma, cystic fibrosis, or severe COPD (baseline FEV1 ≤&#xD;
             40% predicted)&#xD;
&#xD;
          -  Active malignancy other than basal cell melanoma or in situ breast cancer&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Chronic liver disease as judged by the investigator that would pose significant risk&#xD;
             to participation&#xD;
&#xD;
          -  Chronic renal disease as judged by the investigator that would pose significant risk&#xD;
             to participation&#xD;
&#xD;
          -  Inability to obtain informed consent from patient or legally authorized representative&#xD;
             (LAR)&#xD;
&#xD;
          -  Pregnant or breastfeeding Use of extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          -  Prisoner status&#xD;
&#xD;
          -  Concurrent treatment with other inhaled investigational agent for COVID-19**&#xD;
&#xD;
          -  Patient, surrogate, or physician not committed to full support (exception: a patient&#xD;
             will not be excluded if he/she would receive all supportive care except for attempts&#xD;
             at resuscitation from cardiac arrest)&#xD;
&#xD;
          -  Moribund patient not expected to survive 24 hours&#xD;
&#xD;
          -  Active hemoptysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Fowler</last_name>
    <phone>6173551834</phone>
    <email>robert.fowler@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Baron, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mayra Alejandra Pinilla Vera</last_name>
      <phone>412-680-1509</phone>
      <email>mapinillavera@bwh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Benjamiin Raby</investigator_full_name>
    <investigator_title>Chief of Respiratory Diseases</investigator_title>
  </responsible_party>
  <keyword>Pulmozyme</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>ARDS</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

